MA38540B1 - Dérivés de naphtyridine utiles comme antagonistes de l'intégrine alpha-v-bêta-6 - Google Patents

Dérivés de naphtyridine utiles comme antagonistes de l'intégrine alpha-v-bêta-6

Info

Publication number
MA38540B1
MA38540B1 MA38540A MA38540A MA38540B1 MA 38540 B1 MA38540 B1 MA 38540B1 MA 38540 A MA38540 A MA 38540A MA 38540 A MA38540 A MA 38540A MA 38540 B1 MA38540 B1 MA 38540B1
Authority
MA
Morocco
Prior art keywords
beta
alpha
derivatives useful
integrin antagonists
naphthyridine derivatives
Prior art date
Application number
MA38540A
Other languages
English (en)
Other versions
MA38540A1 (fr
Inventor
Niall Andrew Anderson
Brendan John Fallon
John Martin Pritchard
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of MA38540A1 publication Critical patent/MA38540A1/fr
Publication of MA38540B1 publication Critical patent/MA38540B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention porte sur un composé de formule (i) ou un sel de celle-ci (i), dans laquelle r1 représente un atome d'hydrogène, un groupe méthyle ou un groupe éthyle, r2 représente un atome d'hydrogène ou un atome de fluor et r3 représente un atome d'hydrogène, un groupe méthyle ou un groupe éthyle.
MA38540A 2013-03-28 2014-03-26 Dérivés de naphtyridine utiles comme antagonistes de l'intégrine alpha-v-bêta-6 MA38540B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1305668.4A GB201305668D0 (en) 2013-03-28 2013-03-28 Avs6 Integrin Antagonists
PCT/EP2014/056013 WO2014154725A1 (fr) 2013-03-28 2014-03-26 Dérivés de naphtyridine utiles comme antagonistes de l'intégrine alpha-v-bêta-6

Publications (2)

Publication Number Publication Date
MA38540A1 MA38540A1 (fr) 2017-02-28
MA38540B1 true MA38540B1 (fr) 2017-10-31

Family

ID=48444909

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38540A MA38540B1 (fr) 2013-03-28 2014-03-26 Dérivés de naphtyridine utiles comme antagonistes de l'intégrine alpha-v-bêta-6

Country Status (38)

Country Link
US (2) US10023568B2 (fr)
EP (2) EP3360876A1 (fr)
JP (1) JP6095847B2 (fr)
KR (2) KR102042141B1 (fr)
CN (1) CN105189499B (fr)
AR (1) AR095768A1 (fr)
AU (1) AU2014243068C1 (fr)
BR (1) BR112015024530A8 (fr)
CA (1) CA2903358A1 (fr)
CL (1) CL2015002860A1 (fr)
CR (1) CR20150509A (fr)
CY (1) CY1120188T1 (fr)
DK (1) DK2989100T3 (fr)
DO (1) DOP2015000251A (fr)
EA (1) EA027305B1 (fr)
ES (1) ES2665597T3 (fr)
GB (1) GB201305668D0 (fr)
HR (1) HRP20180528T1 (fr)
HU (1) HUE036750T2 (fr)
IL (1) IL241184A0 (fr)
LT (1) LT2989100T (fr)
MA (1) MA38540B1 (fr)
ME (1) ME02987B (fr)
MX (1) MX363288B (fr)
NO (1) NO2989100T3 (fr)
NZ (1) NZ629025A (fr)
PE (1) PE20151606A1 (fr)
PH (1) PH12015502232B1 (fr)
PL (1) PL2989100T3 (fr)
PT (1) PT2989100T (fr)
RS (1) RS57220B1 (fr)
SG (1) SG11201506813QA (fr)
SI (1) SI2989100T1 (fr)
SM (1) SMT201800247T1 (fr)
TW (1) TWI632143B (fr)
UA (1) UA114952C2 (fr)
UY (1) UY35505A (fr)
WO (1) WO2014154725A1 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE057203T2 (hu) 2013-09-24 2022-04-28 Fujifilm Corp Új nitrogén-tartalmú vegyület vagy sója, vagy azok fémkomplexe
GB201417094D0 (en) * 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417002D0 (en) * 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
GB201417018D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417011D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
CA2978026A1 (fr) 2015-03-11 2016-09-15 Glaxosmithkline Intellectual Property Development Limited Proteines de liaison a la tslp
GB201615588D0 (en) 2016-09-14 2016-10-26 Glaxosmithkline Ip Dev Ltd TSLP Binding Proteins
GB201604589D0 (en) * 2016-03-18 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical compound
GB201604680D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
GB201604681D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
PL3538528T3 (pl) * 2016-11-08 2021-05-31 Bristol-Myers Squibb Company Amidy pirolu jako inhibitory integryny alfa v
EA201991123A1 (ru) 2016-11-08 2019-11-29 ИНДАЗОЛОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ АНТАГОНИСТОВ ИНТЕГРИНА αV
BR112019009245A2 (pt) 2016-11-08 2019-07-16 Bristol-Myers Squibb Company azol amidas e aminas como inibidores de alfav integrina
CA3042710A1 (fr) 2016-11-08 2018-05-17 Bristol-Myers Squibb Company Composes mono et spirocycliques contenant du cyclobutane et de l'azetidine en tant qu'inhibiteurs de l'integrine .alpha.v
WO2018089353A1 (fr) 2016-11-08 2018-05-17 Bristol-Myers Squibb Company Acides propioniques à substitution en position 3 en tant qu'inhibiteurs d'intégrine alpha v
EP3558303A4 (fr) 2016-12-23 2020-07-29 Pliant Therapeutics, Inc. Composés acides aminés et leurs procédés d'utilisation
EP3760202A1 (fr) 2017-02-28 2021-01-06 Morphic Therapeutic, Inc. Inhibiteurs de l'intégrine (alpha-v) (bêta-6)
IL316954A (en) * 2017-02-28 2025-01-01 Morphic Therapeutic Inc (Alpha-V)(beta-6)integrin inhibitors
BR112020008893A2 (pt) 2017-11-07 2020-10-13 Bristol-Myers Squibb Company derivados de pirrolopirazina como inibidores de alfa v integrina
DK3761980T3 (da) 2018-03-07 2024-01-29 Pliant Therapeutics Inc Aminosyreforbindelser og fremgangsmåder til anvendelse
TWI841573B (zh) 2018-06-27 2024-05-11 美商普萊恩醫療公司 具有未分支連接子之胺基酸化合物及使用方法
UY38353A (es) 2018-08-29 2020-03-31 Morphic Therapeutic Inc Inhibición de integrina alfavbeta6
EP3843728B1 (fr) * 2018-08-29 2025-04-30 Morphic Therapeutic, Inc. Inhibiteurs de l'intégrine (alpha-v)(bêta -6)
UY38352A (es) 2018-08-29 2020-03-31 Morphic Therapeutic Inc Inhibidores de integrina alfavbeta6
WO2020047208A1 (fr) 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. Inhibiteurs de l'intégrine (alpha-v)(bêta-6)
GB202010626D0 (en) 2020-07-10 2020-08-26 Univ Nottingham Compound
WO2022183360A1 (fr) * 2021-03-02 2022-09-09 Tsao Yeou Ping Peptides synthétiques courts et leurs utilisations pour le traitement de la sécheresse oculaire
WO2024129931A1 (fr) * 2022-12-14 2024-06-20 Alnylam Pharmaceuticals, Inc. LIGANDS DE L'INTÉGRINE ALPHA-V BÊTA-6 (ανβ6) POUR UNE DISTRIBUTION EXTRA-HÉPATIQUE
CN121079296A (zh) * 2022-12-27 2025-12-05 普利安特治疗公司 α-v-β-8整合素抑制剂及其用途
WO2025259747A2 (fr) 2024-06-12 2025-12-18 Alnylam Pharmaceuticals, Inc. Compositions d'arni de protéine kinase myotonique de dystrophie (dmpk) et leurs procédés d'utilisation
WO2025259743A1 (fr) 2024-06-12 2025-12-18 Alnylam Pharmaceuticals, Inc. Composés conjugués doubles pour administration extrahépatique

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
BR9813769A (pt) 1997-12-17 2000-10-10 Merck & Co Inc Composto, composição farmacêutica, e, processos para fabricar a mesma, para evocar um efeito antagonizante do receptor da integrina em um mamìfero em necessidade deste, para tratar ou prevenir uma condição mediada pelo antagonismo de um receptor da integrina em um mamìfero em necessidade deste, para inibir a reabsorção óssea em um mamìfero em necessidade deste, e para tratar o desenvolvimento tumoral em um mamìfero em necessidade deste.
EP1047425A4 (fr) 1997-12-17 2009-04-22 Merck & Co Inc Antagonistes du recepteur de l'integrine
DZ3263A1 (fr) 1999-06-02 2000-12-07 Merck & Co Inc Antagonistes du recepteur de l'alpha v integrine
AU748949B2 (en) 1999-06-23 2002-06-13 Merck & Co., Inc. Integrin receptor antagonists
WO2001024797A1 (fr) 1999-10-04 2001-04-12 Merck & Co., Inc. Antagonistes des recepteurs d'integrine
CN1414966A (zh) * 1999-11-08 2003-04-30 麦克公司 用于制备咪唑烷酮αu蛋白拮抗剂的方法和中间体
US7119098B2 (en) 2000-06-15 2006-10-10 Pharmacia Corporation Heteroarylakanoic acids as intergrin receptor antagonists
US7056909B2 (en) 2000-07-26 2006-06-06 Merck & Co., Inc. Alpha v integrin receptor antagonists
WO2002022616A2 (fr) 2000-09-14 2002-03-21 Merck & Co., Inc. Antagonistes du recepteur des integrines alpha v
EP1349548A4 (fr) 2001-01-03 2004-06-02 Merck & Co Inc Methodes et compositions de traitement d'une parodontopathie
DE10112771A1 (de) * 2001-03-16 2002-09-26 Merck Patent Gmbh Inhibitoren des Integrins alpha¶v¶beta¶6¶
MY130622A (en) 2001-11-05 2007-07-31 Novartis Ag Naphthyridine derivatives, their preparation and their use as phosphodiesterase isoenzyme 4 (pde4) inhibitors
MXPA04008870A (es) 2002-03-13 2005-06-17 Biogen Idec Inc Anticuerpos anti-avb6.
US20040224986A1 (en) 2002-08-16 2004-11-11 Bart De Corte Piperidinyl targeting compounds that selectively bind integrins
BR0317600A (pt) 2002-12-20 2005-11-29 Pharmacia Corp ácidos heteroarilalcanóicos como derivados de antagonistas de receptor de integrina
US6932865B2 (en) 2003-04-11 2005-08-23 Lockheed Martin Corporation System and method of making single-crystal structures through free-form fabrication techniques
PL1699512T3 (pl) 2003-11-03 2012-11-30 Glaxo Group Ltd Urządzenie do dozowania płynów
US7705018B2 (en) 2007-03-23 2010-04-27 Amgen Inc. Substituted quinolines and their uses in treatment of inflammatory and related conditions
US8563566B2 (en) 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
EP2211615A4 (fr) 2007-10-22 2010-10-13 Glaxosmithkline Llc Dérivés de pyridosulfonamide en tant qu'inhibiteurs de pi3 kinase
WO2011111880A1 (fr) 2010-03-08 2011-09-15 주식회사 메디젠텍 Préparation pharmaceutique pour le traitement ou la prévention de maladies dues à l'export nucléaire de gsk3, comprenant un composé inhibant l'export nucléaire de gsk3
WO2015048819A1 (fr) 2013-09-30 2015-04-02 The Regents Of The University Of California Composés d'intégrine anti-aphavbêta1 et méthodes correspondantes
GB201417002D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
GB201417018D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417094D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417011D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
EP3925959A1 (fr) 2015-02-19 2021-12-22 OcuTerra Therapeutics, Inc. Dérivés fluorés de l'acide 3-(2-oxo-3-(3-(5,6,7,8-tétrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoïque et leurs utilisations
CA2981371A1 (fr) 2015-03-10 2016-09-15 The Regents Of The University Of California Inhibiteurs anti-integrine alphavbeta1 et methodes d'utilisation associees
GB201604589D0 (en) 2016-03-18 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical compound
GB201604680D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
GB201604681D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds

Also Published As

Publication number Publication date
LT2989100T (lt) 2018-05-25
PH12015502232A1 (en) 2016-02-01
EP2989100B1 (fr) 2018-02-28
HK1214262A1 (en) 2016-07-22
TW201533042A (zh) 2015-09-01
BR112015024530A2 (pt) 2017-07-18
CY1120188T1 (el) 2018-12-12
NO2989100T3 (fr) 2018-07-28
TWI632143B (zh) 2018-08-11
MX363288B (es) 2019-03-19
PT2989100T (pt) 2018-05-18
RS57220B1 (sr) 2018-07-31
US10023568B2 (en) 2018-07-17
US20180291022A1 (en) 2018-10-11
UY35505A (es) 2014-10-31
US20160280705A1 (en) 2016-09-29
KR102042141B1 (ko) 2019-11-07
CR20150509A (es) 2016-03-04
NZ629025A (en) 2017-05-26
MA38540A1 (fr) 2017-02-28
JP6095847B2 (ja) 2017-03-15
EA027305B1 (ru) 2017-07-31
DOP2015000251A (es) 2016-02-29
EP3360876A1 (fr) 2018-08-15
US10450312B2 (en) 2019-10-22
WO2014154725A1 (fr) 2014-10-02
KR20150135790A (ko) 2015-12-03
CN105189499B (zh) 2016-09-28
SMT201800247T1 (it) 2018-07-17
EA201591503A1 (ru) 2016-04-29
PH12015502232B1 (en) 2018-09-26
HRP20180528T1 (hr) 2018-05-04
EP2989100A1 (fr) 2016-03-02
BR112015024530A8 (pt) 2019-12-10
SG11201506813QA (en) 2015-10-29
KR20170103033A (ko) 2017-09-12
AR095768A1 (es) 2015-11-11
ME02987B (fr) 2018-10-20
HUE036750T2 (hu) 2018-07-30
MX2015013742A (es) 2016-02-29
PL2989100T3 (pl) 2018-07-31
CN105189499A (zh) 2015-12-23
AU2014243068A1 (en) 2015-10-08
ES2665597T3 (es) 2018-04-26
DK2989100T3 (en) 2018-04-23
AU2014243068C1 (en) 2017-05-25
SI2989100T1 (en) 2018-06-29
CA2903358A1 (fr) 2014-10-02
KR101775085B1 (ko) 2017-09-05
IL241184A0 (en) 2015-11-30
JP2016515557A (ja) 2016-05-30
PE20151606A1 (es) 2015-11-24
CL2015002860A1 (es) 2016-03-28
UA114952C2 (uk) 2017-08-28
AU2014243068B2 (en) 2017-01-05
GB201305668D0 (en) 2013-05-15

Similar Documents

Publication Publication Date Title
MA38540A1 (fr) Dérivés de naphtyridine utiles comme antagonistes de l'intégrine alpha-v-bêta-6
EA201690019A1 (ru) Производное аминотриазина и содержащая его фармацевтическая композиция
JO3261B1 (ar) مشتق بيريدين أحادي الحلقة
MA38390A1 (fr) Composés tétrahydropyrrolothiazines
MA38583A1 (fr) Dérivés de dolastatine 10 et d'auristatines
MA35172B1 (fr) Melanges pestticides contenant des derives d'isoxazoline
MY177250A (en) Novel nicotinamide derivative or salt thereof
MA34006B1 (fr) Derives de dihydrofurane utilises comme composes insecticides
MY156669A (en) Pesticidal composition and its use
MA38404A1 (fr) Nouveaux dérivés de pyridine
MA35663B1 (fr) Dérivés de [1, 2, 3]triazolo [4, 5 -d] pyrimidine comme agonistes des récepteurs aux cannabinoïdes 2
MX372721B (es) Ánalogos halogenados de agentes antifi-broticos.
MA35893B1 (fr) Dérivés d'amide hétérocyclique comme antagonistes du récepteur p2x7
BR112018004447A2 (pt) derivado de biarila e medicamento contendo o mesmo
BR112012027378A2 (pt) composto pesticida e seu uso
MX2018001317A (es) Inhibidores del virus sincitial respiratorio.
PH12016500152A1 (en) Novel triazine derivative
MA39305A3 (fr) Dérivés d'éthynyle
FR3020809B1 (fr) Derives de 4-vinyl-2cyclopentene-1-one leur preparation et leur utilisation en tant qu'agent antibiotique
MA20150280A2 (fr) Dérivés d'aryléthynyle
MA38010B1 (fr) Dérivés d'éthynyl utilisés en tant que modulateurs de l'activité des récepteurs mglur5
IN2012DN01251A (fr)
MX358151B (es) Derivado de sitaxentan.
BR112016029347A2 (pt) ?repelente de animal roedor, e, método para repelir um animal roedor?
EA201400269A1 (ru) Способ синтеза соединений 7,8-диметокси -1,3-дигидро-2h-3-бензазепин-2-она и применение в синтезе ивабрадина